Navigation Links
China Bio-Immunity Corporation Completes Share Exchange and Reverse Merger
Date:8/6/2008

13.2 Million Common Shares Issued and Listed on OTCBB

DALIAN, China, Aug. 6 /Xinhua-PRNewswire-FirstCall/ -- China Bio-Immunity Corporation (OTC Bullets and Board: CHHB) (''China Bio-Immunity" or "the Company''), today announced that it has entered into a share exchange agreement with Lawford Asia Limited (''Lawford''). According to the share exchange transaction agreement, China Bio-Immunity acquired all of the issued and outstanding stock of Lawford in exchange for the issuance of 13,246,697 shares of its common stock.

Lawford is the holding company of Dalian Jingang-Andi Bio-Products Co. Ltd. (''JGAD''). Under the share exchange agreement, China Bio-Immunity will carry out the business of JGAD as its sole line of business. JGAD is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily within China.

The Company's revenue generating product portfolio is primarily comprised of Rabies Vaccine for Human Use with Vero Cell, a unique biological product that is used to effectively control and combat rabies disease, and Mumps Vaccine, which is produced from the live, attenuated S79 strain of the mumps virus. In addition to its current products, the Company's product pipeline includes five next-generation vaccine-based prophylactics and therapeutics in various stages of development for both the prevention and treatment of various viruses and infectious diseases. The Company believes that the potential launch of its pipeline products will bring significant market opportunities in the next three to five years.

In conjunction with the share exchange agreement, the Company today filed a Current Report on Form 8-K with the Securities and Exchange Commission, which discloses detailed information about the Company and its subsidiaries, including financial statements for the fiscal years ended December 31, 2006 and 2007, and the three months period ended March 31, 2008.

In the first quarter of 2008, the Company generated revenue of $6.3 million, representing an increase of 506% from $1.0 million in the first quarter of 2007. Net income increased 961% to $2.2 million in the first quarter of 2008, from $0.2 million in the first quarter of 2007. The significant increase in revenue and net income was primarily attributed to the new regulation implemented by the State Food and Drug Administration (''SFDA'') at the end of 2006. The new regulation placed heightened restrictions on product quality. As a result, a significant number of the Company's competitors' products failed to meet the heightened requirements set forth by the SFDA. On the contrary, each batch of vaccine manufactured by JGAD passed the relevant quality inspection; consequently the Company experienced significant increase in sales volume and its brand name, ''JGAD'', gained an outstanding reputation.

In the fiscal year ended December 31, 2007, the Company generated revenue of $24.9 million, representing an increase of 256% from $7.0 million in the fiscal year ended December 31, 2006. Net income increased 278% to $14.0 million in 2007, from $3.7 million in 2006. Increased sales of the Rabies Vaccine, as well as the launch of the Mumps Vaccine during the fiscal year 2007, drove the improved financial performance.

Mr. Quanfeng Wang, Chief Executive Officer of China Bio-Immunity, stated, "Today's transaction provides our Company with a solid platform for growth as we aggressively pursue opportunities in China's vaccine market. We believe that we are well-positioned to compete in this fast-developing sector given our strong JGAD brand, diverse product portfolio, proven R&D capabilities, established sales and marketing network and favorable cost structure. With access to the U.S. capital markets, we believe we will be in a compelling position to further strengthen our distribution network both inside and outside of China, develop innovative new products, and provide exciting opportunities for our team to grow our business."

About China Bio-Immunity

Based in Dalian, China, China Bio-Immunity develops, produces, manufactures and markets internally developed vaccine-based prophylactics and therapeutics. The Company has sales and marketing efforts in the 24 main provinces and major cities in the People's Republic of China (''P.R.C.'') and its principal products, its Rabies Vaccine and Mumps Vaccine, are sold and distributed by a network of approximately 100 wholesale distributors, as well as through more than 2,200 retail customers. In addition to the current distribution structure, the Company plans to further market its products through distribution agreements with local agents in several developing countries, including, but not limited to India, South Africa, and countries throughout Southeast Asia. To learn more about the Company, visit http://www.jgad-bio.com .

Safe Harbor Statement

This press release includes certain statements that are not descriptions of historical facts, but are forward-looking statements. Such statements include, among others, those concerning our expected financial performance and strategic and operational plans, our future operating results, our expectations regarding the market for security and surveillance products, our expectations regarding the continued growth of the security and surveillance market, as well as all assumptions, expectations, predictions, intentions or beliefs about future events. You are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause our actual results to differ materially from those anticipated, expressed or implied in the forward-looking statements. These risks and uncertainties include, but not limited to, the factors mentioned in the ''Risk Factors'' section of the Form 8-K of the Share Exchange Agreement that has been filed with the Securities Exchange Commission, or SEC. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis retrieval system (EDGAR) at http://www.sec.gov . The words ''believe'', ''expect'', ''anticipate'', ''project'', ''targets'', ''optimistic'', ''intend'', ''aim'', ''will'' or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward- looking statements. The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

For more information, please contact:

Ashley M. Ammon

Integrated Corporate Relations, Inc.

Tel: +1-203-682-8200

Christine Duan

Integrated Corporate Relations, Inc.

Tel: +1-203-682-8200


'/>"/>
SOURCE China Bio-Immunity Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd.
2. UNC School of Social Work helps China tackle growing pains
3. Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics
4. China Shenghuo Pharmaceutical Retains Grayling Global As Investor Relations Counsel
5. China Medical Technologies to Announce Financial Results for the First Quarter Ended June 30, 2008 on August 4, 2008
6. China Medicine Corporation Obtains Australian Patent for rADTZ
7. China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company
8. AmeriCares Purchases 2nd BLU-MED Deployable Field Hospital for China Earthquake Relief
9. Closing coal-burning power plant in China and improved cognitive development in children
10. China Kangtai Cactus Biotech Inc. Launches Cactus Cattle Feed and Cactus Fish Feed
11. AmeriCares Meets Long-Term Health Needs of Disaster Victims in China and Myanmar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen ... LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug & ... is also a Lead Sponsor of the conference. , Cohen, who chairs the firm’s ...
(Date:12/2/2016)... ... 2016 , ... For over twenty-four years, Doctors on Liens has published a directory ... high quality medical care. When the company started in 1997, the directory was a ... day and the now ten-page directory features a vast array of medical specialists ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. ... Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at an early ... medicine is about more than making diagnoses and prescribing medicine,” he states. “It is ...
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... ... surgeon in Beverly Hills, California, will be included in the 2016 “Guide to ... to exceptional professionals based on the amalgamation of their education, experience, and professional ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 ... to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... of ropeginterferon alfa-2b versus HU AOP will ... trial CONTINUATION-PV to obtain European marketing authorization in the coming ... to the FDA as it seeks approval for commercialization in ...
(Date:12/4/2016)... NEW ORLEANS , Dec. 2, 2016  Former Attorney ... Foti, Jr., Esq. , a partner at the law firm ... has commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in ... an "antitrust investigation by the Justice Department, begun about two ...
(Date:12/4/2016)... Dec. 3, 2016  Results from the Phase II ... anti-P-selectin antibody, reduced the median annual rate of sickle ... (1.63 vs 2.98, p=0.010) in patients with or without ... data are being featured in the official press briefing ... (ASH) Annual Meeting and presented during the Plenary Scientific ...
Breaking Medicine Technology: